trial · primary record
4.5mg daily dose of naltrexone
Central Neuropathic Pain
| Phase | Phase 2 |
|---|---|
| Status | COMPLETED |
| Sponsor | Unknown |
| Enrolment | 11 |
| Primary completion | 2026-06-30 |
| Primary endpoint | Evaluate LDN in the treatment of CNP after SCI |
| Registry ID | NCT06723561 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-02T15:46:16.864Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06723561
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.